Pliant Therapeutics, Inc.

NasdaqGS:PLRX 주식 보고서

시가총액: US$684.7m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Pliant Therapeutics 미래 성장

Future 기준 확인 2/6

Pliant Therapeutics 의 수익은 연간 2.5% 감소할 것으로 예상되는 반면, 연간 수익은 70.9% 로 증가할 것으로 예상됩니다. 70.9% 연간. EPS는 연간 5.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 -70.8% 로 예상됩니다.

주요 정보

-2.3%

수익 성장률

6.0%

EPS 성장률

Pharmaceuticals 수익 성장27.6%
매출 성장률71.5%
향후 자기자본 수익률-70.8%
애널리스트 커버리지

Good

마지막 업데이트21 Jun 2024

최근 미래 성장 업데이트

Recent updates

Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Jun 07
Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Feb 27
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Jul 21
Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?

Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Mar 13
Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?

Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Sep 10
Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?

Pliant Therapeutics: Wait For A Better Price To Get In

Aug 20

Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M

Aug 08

Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Jul 28
Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?

Pliant's PLN-74809 gets FDA fast track status for liver disease

Jul 21

Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals

Jul 11

Pliant: Major Catalyst Expected Beginning Of 2023

Jun 03

We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Apr 22
We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate

Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

Dec 29
Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation

We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Sep 07
We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth

Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

May 17
Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 13
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

Mar 22
Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans

We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Jan 21
We're Not So Sure You Should Rely on Pliant Therapeutics's (NASDAQ:PLRX) Statutory Earnings

Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Dec 17
Is Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) 6.5% ROE Worse Than Average?

Pliant Therapeutics (PLRX) Presents At Piper Sandler 32nd Annual Virtual Healthcare Conference - Slideshow

Dec 02

수익 및 매출 성장 예측

NasdaqGS:PLRX - 애널리스트의 미래 추정치 및 과거 재무 데이터 (USD Millions )
날짜수익수익잉여 현금 흐름작전 현금평균 애널리스트 수
12/31/20264-275-235-21910
12/31/20256-246-199-19612
12/31/20242-208-142-16012
3/31/20240-171-119-116N/A
12/31/20232-161-117-116N/A
9/30/20234-155-124-122N/A
6/30/20235-144-106-105N/A
3/31/202310-133-106-104N/A
12/31/202210-123-96-95N/A
9/30/202210-113-85-83N/A
6/30/202210-109-89-87N/A
3/31/20227-103-85-82N/A
12/31/20218-97-77-75N/A
9/30/202110-92-74-72N/A
6/30/202113-81-67-65N/A
3/31/202115-75-40-38N/A
12/31/202042-42-39-37N/A
9/30/202094181516N/A
6/30/202090191617N/A
3/31/20208620-6-5N/A
12/31/201957-7-4-3N/A
3/31/2019N/A-43-33-32N/A
12/31/2018N/A-35-31-28N/A

애널리스트 미래 성장 예측

수입 대 저축률: PLRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: PLRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: PLRX 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: PLRX 의 수익(연간 70.9% ) US 시장( 8.7% 보다 빠르게 성장할 것으로 예상됩니다. 8.7% 연간).

고성장 수익: PLRX 의 수익(연간 70.9% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.


주당 순이익 성장 예측


미래 자기자본 수익률

미래 ROE: PLRX (는) 3년 내에 수익성이 없을 것으로 예상됩니다.


성장 기업 발견